Atara Biotherapeutics (ATRA) Income from Continuing Operations (2013 - 2026)
Atara Biotherapeutics (ATRA) posted Income from Continuing Operations of 4145000.0 for Q1 2026, down 22.34% on a QoQ basis from 3388000.0 in Q4 2025, and down 110.91% year-over-year from 38010000.0 in Q1 2025.
Atara Biotherapeutics (ATRA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Atara Biotherapeutics' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 4145000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 110.91% year-over-year to 4145000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9449000.0 (up 39.59% YoY) and the FY2025 annual result came in at 32706000.0, up 138.3% from the prior year.
- Income from Continuing Operations was 4145000.0 for Q1 2026 at Atara Biotherapeutics, down from 3388000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 38010000.0 in Q1 2025 and bottomed at 88105000.0 in Q1 2022.
- A 5-year average of 33015882.35 and a median of 21909000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 485.08% — and 2025, when it jumped 219.71%.
- Atara Biotherapeutics' Income from Continuing Operations stood at 74572000.0 in 2022, then increased by 18.94% to 60450000.0 in 2023, then soared by 79.0% to 12693000.0 in 2024, then soared by 73.31% to 3388000.0 in 2025, then fell by 22.34% to 4145000.0 in 2026.
- Business Quant data shows ATRA's Income from Continuing Operations at 4145000.0 in Q1 2026, 3388000.0 in Q4 2025, and 4303000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | -4.30 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 38.01 Mn |
| Dec 31, 2024 | -12.69 Mn |
| Sep 30, 2024 | -21.91 Mn |
| Jun 30, 2024 | -19.05 Mn |
| Mar 31, 2024 | -31.75 Mn |
| Dec 31, 2023 | -60.45 Mn |
| Sep 30, 2023 | -69.80 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -74.77 Mn |
| Dec 31, 2022 | -74.57 Mn |
| Sep 30, 2022 | -84.09 Mn |
| Jun 30, 2022 | 18.47 Mn |
| Mar 31, 2022 | -88.11 Mn |
| Dec 31, 2021 | -93.56 Mn |
| Sep 30, 2021 | -84.66 Mn |
| Jun 30, 2021 | -83.79 Mn |